A delivery system based on poly(lactic-co-glycolic acid) polymer (PLGA) microparticles has been developed for parenteral administration of the local anesthetic prilocaine in its free base form. Both drug-free and drug-loaded microparticles, prepared by a double-emulsion-evaporation method, were characterized for mean size by Laser Diffraction Analysis, while their morphology was investigated by scanning electron microscopy. The preparation technique allowed obtainment of homogeneous microparticles of about 25 µm diameter, suitable for subcutaneous administration. The encapsulation efficiency, determined by both direct and indirect methods, was around 36-38%. Differential Scanning Calorimetry was used to characterize the solid state of the raw materials, assess drug-polymer compatibility and miscibility and highlight possible modifications of the components induced by the preparation method. In vitro release studies showed a sustained release profile, with about 80% of drug released after the first 24 h. The anesthetic effect of the formulation was evaluated in vivo on rats, according to the test of cutaneous trunci muscle reflex. Administration of prilocaine base as PLGA microparticles allowed to significantly enhance both extent (60% AUC increase) and duration (100% increase) of the anesthetic effect in the animal model, in comparison with the equivalent dose of prilocaine hydrochloride aqueous solution.
Introduction
Local anesthetic agents are widely used for the control of acute and chronic pain, particularly in dental practice and in surgery. Although several new molecules have been developed over the last years, some critical drawbacks still remain to be solved in order to achieve a more effective therapeutic use of these drugs. In particular, drug parenteral administration for injection requires a sufficient aqueous solubility, which is generally achieved by the use of their hydrochloride form. On the other hand, this often implies a fast removal of the drug from the site of injection, reinforced by the vasodilator activity shown by many local anesthetics. This generally implies an effect limited in terms of duration and intensity, thus requiring high drug concentrations or repeated injections. The co-administration of a vasoconstrictor, generally epinephrine, is the most common approach to overcome this inconvenience and prolong the duration of the anesthetic action. However, the use of vasoconstrictors presents different drawbacks. First of all, it is not advisable for many patients, such as individuals with high blood pressure, by-pass surgery, prior myocardial infarction, angina, uncontrolled diabetics, uncontrolled thyroid disorders or treated with tricyclic anti-depressives (Perusse et al., 1992) . Secondly, solutions containing vasoconstrictors are more acidic, primarily due to the need of using anti-oxidant preservatives, such as sodium metabisulphite; consequently, their use is commonly associated with major pain and patient discomfort during the injection process, due to the reduced pH (Kramp et al., 1999) . Furthermore, vasoconstrictors have been shown to interfere with pulpal blood flow by reducing the arterioles and venules diameter, possibly causing pulpitis (Odor et al., 1994 , Yu et al., 2002 .
Therefore, there are several reasons to consider the potential advantages of developing innovative formulations, able to enhance the therapeutic efficacy of anesthetic drugs in terms of both duration and intensity of the effect, without the employment of vasoconstrictors. Over the last years, several technological approaches have been investigated in order to overcome these limitations, designed to enhance and prolong the therapeutic effect of local anesthetics and also improve their safety profile, reducing their dosage and dose-related toxicity . These include complexation with cyclodextrins (Karashima et al., 2007; de Araujo et al., 2008; Jug et al., 2010; Bragagni et al., 2010a; Cereda et al., 2012) or entrapment in colloidal vesicles (Mura et al., 2007; Elsaie and Bauman, 2008; Bragagni et al. 2010b; Tofoli et al., 2011; Tong et al., 2014) or in micro or nanoparticles (Grillo et al., 2010 , Melo et al., 2014 .
Prilocaine is an amino-amide-type local anesthetic widely used as hydrochloride salt for intravenous (i.v.) regional anesthesia and in dentistry. However, its high water solubility gives rise to a fast removal from the tissues by the bloodstream, thus reducing the duration of the anesthetic effect and making it necessary repeated injections to achieve an adequately long pain relief (Malamed, 2012) . In a previous work we tested different types of polylactic acid (PLA) polymers for the preparation of microparticles loaded with prilocaine hydrochloride, intended to obtain a controlled and prolonged delivery of the drug (Bragagni et al., 2013) .
However, the therapeutic outcome of prilocaine base should potentially be more effective than the corresponding hydrochloride form, being the non-ionized form more lipophilic and more permeable through the biologic membranes. Nevertheless, the very low aqueous solubility and limited stability of the drug base form strongly restrict its use, giving rise to problems in the preparation of classical parenteral formulations. In fact, no parenteral formulations of prilocaine base are currently available on the market.
Therefore, as a continuation of our studies, in the present work we have explored the possibility of preparing biodegradable microparticles, suitable for parenteral administration, loaded with prilocaine in its base form, focused to improve the drug bioavailability and therapeutic effectiveness. Poly(lactic-co-glycolic acid) polymer (PLGA) was selected as polymeric matrix, considering the extensive evidences attesting its safety in use, high biocompatibility, with generation of a very mild tissue reaction, and its ability to provide a controlled drug release (Danhier et al., 2012; Pandey and Jain, 2015) . Positive results on the ability of PLGA-microparticle formulations in entrapping and properly modulating the release of a variety of drugs, included local anesthetics such as bupivacaine (Le Corre et al., 2002) , lidocaine (Klose et al., 2008) or prilocaine (Delplace et al., 2012) , have been reported. In particular, the factors influencing the release of prilocaine base from PLGA microparticles have recently been investigated (Gasmi et al., 2015) . However, at the best of our knowledge, no in vivo studies have been performed until now to evaluate the actual therapeutic effectiveness of such prilocaine base parenteral delivery systems.
In the present study, prilocaine-loaded PLGA microparticles were prepared by a double emulsion method and fully characterized in terms of dimensions, homogeneity, morphology, drug encapsulation efficiency, and in vitro drug release behavior. The duration and intensity of the anesthetic effect of the developed formulation was evaluated in vivo by subcutaneous injection to rats, using the block of Cutaneous Trunci Muscle Reflex (CTMR) as a model of infiltration anesthesia, in comparison with the corresponding aqueous solutions of prilocaine hydrochloride salt.
Materials and methods

Materials
Poly(D,L-lactic-co-glycolic acid) polymer (PLGA, Resomer RG504H, 50:50 lactic acid-glycolic acid) was purchased from Boehringer Ingelheim (Ingelheim, Germany). Polyvinyl alcohol (PVA), dichloromethane, prilocaine hydrochloride (PRL.HCl), and prilocaine free base (PRL) were purchased from Sigma Aldrich (Spain). Water was obtained from a Milli-Q water purification system (Millipore, Billerica, MA, USA). Phosphate buffer solution 0.1 M pH 7.4 was prepared according to Eur. Pharm. 7th Ed. All others chemicals and solvents used in this study were of analytical reagent grade.
Preparation of microparticles
Drug-free and drug-loaded microparticles were prepared by a waterin-oil-in-water (W1/O/W2) double emulsion evaporation method (Klose et al., 2006) . Drug-loaded microparticles were prepared by adding 2 mL of a suspension of 115.5 mg of prilocaine (0.050-0.100 µm sieve granulometric fraction) in distilled water into a solution of PLGA (850 mg) in dichloromethane (20 mL) and emulsifying under stirring for 5 min at 24,000 rpm with a high-speed homogenizer (Ultra-Turrax T25 Basic, IKA-Werke GmbH, Staufen, Germany). This primary W1/O emulsion was added to 50 mL of an outer aqueous solution of PVA (1% w/w) and submitted for 30 min to paddle stirring (Eurostar digital, IKA, Germany) at 800 rpm in order to obtain a stable double-emulsion W1/ O/W2. The system was then left under stirring at 200 rpm for further 3.5 h to completely remove the organic solvent. Microparticles were separated by filtration (TCTP membrane filter, polycarbonate, pore size 10 µm, Merck Millipore), rinsed three times with deionized water and finally freeze-dried (Flexi-Dry MPTM, FTS® Systems, NY, USA). Drugfree microparticles were obtained according to the same procedure, without prilocaine.
The percentage yield of microparticle production was determined using the following equation:
[weight of microparticles/(weight of polymer weight of the drug)] 100
Morphological and size analyses of microparticles
The morphological properties of microparticles, before and after drug release tests, were investigated by SEM microscopy (JEOL EOS 6335F microscope, Tokyo, Japan). Before analysis, samples were goldcoated under vacuum (K550X ion sputter, Emitech, UK) 3 min at 25 mA.
Mean diameter and polydispersity index (PDI) of the microparticles were determined by using a Laser Diffraction Particle Size Analyzer (S3500 Microtrac, Meerbusch, Germany). Samples were prepared by suspending about 5 mg of microparticles in 3 mL of deionized water and sonicating 1 min in a water bath to prevent aggregation phenomena. Each analysis was carried out in triplicate.
Encapsulation efficiency and drug loading capacity of microparticles
The drug encapsulation efficiency was determined by both an indirect and a direct method.
For the indirect method, the external water phase (W2) was recovered after microparticle filtration and the concentration of the drug dissolved was spectrometrically assayed at 240 nm. An aqueous solution of PVA 1% w/w was used as blank and for the preparation of the calibration curve (R 2 =0.9998). Encapsulation efficiency (EE%) was calculated using the following equation:
where W free is the amount of free drug in the aqueous phase after microparticle separation and W tot the total amount of drug initially used.
For the direct method, an accurately weighed sample of loaded microparticles (20 mg) was dissolved in dichloromethane (2 mL). The drug was then extracted in HCl 0.1 M, using aliquots of 5 mL and maintaining the suspension under stirring. The procedure was repeated four times and the drug was spectrometrically assayed at 230 nm in every aliquot. The blank used for the analyses and for the calibration curve (R of pure drug and submitted to the same extraction procedure. The average yield of the drug extraction procedure was 96.7 ± 0.4% (n = 3).
Encapsulation efficiency (EE%) was calculated according to the following equation:
ins tot where W ins was the amount of drug inside the microparticles, and W tot the total amount of drug initially used. Drug loading capacity (LC%) was determined using the following equation:
ins MPtot where W ins was the amount of drug inside the microparticles, and W MPtot the total weight of microparticles. All determinations were carried out in triplicate.
In vitro drug release studies
In vitro experiments were performed in order to simulate and examine the drug release behavior after the formulation injection. Briefly, weighed microparticle samples (50 mg) were put in vials with 3 mL of pH 7.4 phosphate buffer, hermetically closed, and horizontally shaken at 50 S/min and 37 ± 2°C in a Clifton NES-28 shaker bath (NickelElectro Ltd., Weston-super-Mare, UK). At given times, 2 mL samples were withdrawn and replaced with an identical volume of fresh medium. The drug amount in the samples was quantified by UV-VIS at 230 nm, using a pH 7.4 phosphate buffer solution as blank and for the calibration curve (R 2 =0.9992). The progressive dilution of the medium was calculated. Release experiments were carried out in triplicate.
At the end of drug release tests, microparticles were recuperated and dried in oven at 40°C overnight. Part of these microparticles was used for observation by SEM microscopy. The remaining part was utilized for quantification of the unreleased drug: an accurately weighed sample of microparticles was dissolved in dichloromethane and extracted in acidic aqueous solution as above described (par. 2.4., direct method).
Differential scanning calorimetry (DSC)
Drug alone, PLGA, drug-free and drug-loaded microparticles were analyzed by differential scanning calorimetry (DSC 820, Mettler Toledo, Switzerland, endowed with a refrigerated cooling system TC100, Huber, Germany). Exactly weighed samples (about 5 mg) were analyzed in pierced aluminum pans. The pure drug was analyzed at a heating rate of 10°C min -1 in a 20-200°C temperature range. For the analyses of pure polymer, drug-free and drug-loaded microparticles, a heat-cool-heat loop was carried out. The thermal phenomena were measured in the second heating cycle of the loop: heating from 20°C to 80°C; 2 min isothermal at 80°C; quenching from 80°C to 20°C; 2 min isothermal at 20°C; heating from 20°C to 200°C. Both heating rate and quenching rate were 10°C min -1 .
In vivo studies
Male Sprague-Dawley Rats (Envigo, Varese, Italy) weighing about 300-350 g at the start of the experimental procedure, were used. Animals were housed in CeSAL (Centro Stabulazione Animali da Laboratorio, University of Florence) and used no less than one week after their arrival. Ten rats were housed per cage (size 26 × 41 cm); animals were kept at 23 ± 1°C, with a 12 h light/dark cycle (light at 7 a.m), and fed on a standard laboratory diet and tap water ad libitum. (McGrath and Lilley, 2015) . All efforts were made to minimize animal suffering and to reduce the number of animals used. The experiments were done on handled animals familiarized with the experimental environment and procedures. The lack of stress behavior (immobilization, absence of exploratory behavior in an open field environment, recurrent defecation, etc.), the absence of a dorsal contractile response to the non-noxious stroking and a significant response to noxious stimuli were considered as sufficient features. As characteristic response to a noxious pinprick, the Cutaneous Trunci Muscle Reflex (CTMR) was investigated. It is defined as the reflex movement of the skin over the back generated by convulsive movements of lateral thoracic-spinal muscles as a consequence of a local stimulus. Inhibition of CTMR was utilized as a model of infiltration anesthesia, according to the method of Khodorova and Strichartz (2000) . Each anesthetic formulation was administered subcutaneously in 0.6 mL solution. The injections produced a round wheal (about 2 cm) of the skin, that was delineated with ink. Six pinpricks were then applied inside this zone, and the number to which the rat failed to respond was measured. The intensity of the local anesthetic effect was quantified on the basis of the number of times the pinprick failed to provoke a reaction. The total lack of 6 responses was considered as 100% CTMR block (100% of maximum possible effect [MPE] ). Measurements (6 pinpricks each) were performed every 15 min up to a full recovery was attained. Each dose was always administered over a naive part of the rat clipped back. Six areas into the rat back were used to test different preparations. All substances were solubilized or suspended in Phosphate Buffered Saline solution (PBS, pH 7.4) and administered in a volume of 0.6 mL. Aqueous solutions of prilocaine hydrochloride were initially administered at different concentrations (0.05%, 0.1%, 0.3% and 0.5% w/v), to evaluate the dose-effect response of the drug. The drug-loaded microparticles were administered at drug concentrations of 0.1% and 0.3%, chosen because they gave the best results in preliminary experiments. The vehicle (PBS) was used as control. Drug-free microparticles were used as blank and administered at the same concentration as in the corresponding drug-loaded formulation.
Behavioral measurements were performed on 6 rats for each treatment. Results were expressed as means ± s.e.m. and the analysis of variance was performed by one way ANOVA. A Bonferroni's significant difference procedure was used as post-hoc comparison. P < 0.05 or 0.01 were considered significant. Data were analyzed with the Origin 9 software (OriginLab, Northampton, USA).
Results and discussion
Characterization of drug-free and drug-loaded microparticles
Preliminary experiments, performed by varying the theoretical drug loading from 3 to 18% (28.9-169.4 mg drug and 771.6-935.0 mg PLGA), allowed selection of the best drug:polymer w/w ratio to use for microparticle preparation (115.5 mg drug and 850.0 mg PLGA, corresponding to a theoretical 12% drug loading), on the basis of the highest entrapment efficiency.
SEM analysis was employed to investigate and compare the morphological appearance of drug-free and drug-loaded microparticles (Fig. 1) .
Drug-free microparticles (Fig. 1a) exhibited a regular spherical shape and smooth surface, without any evidence of pores or cavities, and a relatively homogeneous distribution in terms of mean dimensions was observed. Interestingly, the aspect of drug-loaded microparticles (Fig. 1b) was different. In fact, even though their mean dimensions were rather similar to those of drug-free microparticles, the particles showed a partially collapsed spherical shape. This effect, not previously observed for other kinds of prilocaine-loaded PLGA microparticles prepared by an oil-in-water (O/W) solvent/extraction/evaporation technique (Delplace et al., 2012; Gasmi et al., 2015) , was then attributed to the different preparation method used in the present study (water-in-oil-in-water (W/O/W) solvent evaporation method) (Jeyanthi et al., 1996; Freitas et al., 2005) . In particular, it could be reasonably hypothesized that the slow solvent removal process allowed to point out a plasticizing effect of prilocaine towards the polymer (Delplace et al., 2012) . In fact such phenomenon was not observed for the corresponding drug-free microparticles.
The drug appeared to be completely dissolved within the polymeric matrix, according to the reported prilocaine saturation solubility in the PLGA phase of about 15% (Delplace et al., 2012 , Gasmi et al., 2015 .
As expected, upon 72 h exposure to the release medium, the surface of microparticles became much more rough and porous, as a consequence of both drug release and matrix erosion phenomena (Fig. 1c) .
Laser Diffraction Particle Size analysis indicated a monomodal distribution of particle size for both drug-free and drug-loaded microparticles and no significant differences were observed between their mean dimensions, according to the results of SEM analysis. The mean diameter values were very suitable for subcutaneous injection, being respectively 24.2 µm ( ± 5.1 µm) and 26.1 µm ( ± 4.3 µm), and clearly smaller and more homogeneous than those of previously developed prilocaine-loaded PLGA microparticles, which were all around 80-90 µm, with an almost large standard deviation of about 38-40% (Gasmi et al., 2015) . Then, the microencapsulation technique proposed in this paper for prilocaine-base provided not only microparticles with narrower size dispersion than the existing ones, but also made their subcutaneous administration easier. In fact, the size lower than 35 µm is suitable for a 23G needle injection without blockage of the syringe mechanism (Whitaker et al., 2001) .
The direct and indirect methods used for the determination of the encapsulation efficacy gave comparable results, resulting in EE% values of 36.0 ± 0.8% (n = 3) and 38.1 ± 0.9% (n = 3), respectively. The corresponding LC% values were 4.8 ± 0.2% and 5.1 ± 0.2%, respectively.
An optimal percentage yield in the microparticle production of M. Bragagni et al. International Journal of Pharmaceutics 547 (2018) 24-30 about 90% was obtained.
In vitro drug release studies
Sink conditions were maintained throughout the experiments, in virtue of the progressive replacement of the solvent (pH 7.4 phosphate buffer) with fresh medium. Fig. 2 shows the release behaviour of prilocaine from the microparticle formulation. A sustained drug release was observed with a biphasic trend, characterized by a relatively initial rapid phase, with the achievement of about 80% drug released after the first 24 h; this was then followed by a slower release phase, where the remaining 20% drug was gradually released during the subsequent 48 h. The mathematical model which better represents the release kinetic is a first order kinetic (R 2 =0.936).
In spite of the great success and extended applications of PLGA microparticles for the development of advanced drug delivery systems, the underlying mechanisms controlling drug release are still not completely understood, owing to the numerous involved phenomena and the different properties of the entrapped drugs (Klose et al., 2006; Klose et al., 2008; Benéitez et al., 2014; Gasmi et al., 2015; Gasmi et al., 2016) . It has been shown that the drug release profile from PLGA microparticles is strongly dependent on its initial loading amount: triphasic profiles (high initial release, slow release and final rapid release phase), or almost mono-phasic profiles (high fast release) were obtained for low or high loading amounts, respectively, while biphasic profiles, as that observed in the present case, were instead observed for intermediate values of initial drug loading (Gasmi et al., 2016) . Moreover, both the device geometry and the type of drug can significantly influence the diffusion kinetic from PLGA-based delivery systems (Klose et al., 2008) . In particular, in the case of prilocaine-loaded PLGA microparticles, the main mechanisms affecting drug release, related to both the drug content in the matrix and its basic nature, can be considered: (i) the different swelling degree and different increase in matrix porosity, upon the progressive drug depletion, with a consequence mobility increase of the residual drug (Gasmi et al., 2015) ; (ii) the quickening of PLGA degradation process, catalyzed by the basic character of prilocaine free base, and consequent gain in drug mobility (Siepmann and Goepferich, 2001 ); (iii) the plasticizing effect of prilocaine towards PLGA, which can promote the PLGA molecular mobility, and, consequently, also the drug mobility (Siepman et al., 2006) .
At the end of the release test, microparticles were recuperated and the drug not released was quantified after disruption of microparticles in organic solvent. For all the samples the amount of prilocaine experimentally determined inside the microparticles corresponded to the expected value based on the drug loading, with a relative error ≤5%.
DSC studies
The results of DSC analysis of pure components, drug-free and drugloaded microparticles are shown in Fig. 3 . In the case of pure PLGA and of microparticles, a heat-cool-heat loop method was utilized, since it proved to be an useful tool to investigate the compatibility and miscibility of drug-polymer mixtures and to highlight possible modifications due to the microparticle preparation protocol (Bragagni et al., 2013; Gasmi et al., 2015) .
The thermal curve of pure drug powder exhibited an endothermic event, starting at about 39°C and peaked at about 44°C, corresponding to the melting of crystalline prilocaine base.
The glass transition of pure PLGA occurred in the 48-55°C range, with a midpoint value at 52°C. No appreciable variations of the glass transition parameters of PLGA were observed in the DSC curve of drugfree microparticles, indicating that the experimental conditions employed for their preparation did not affect the polymer properties. On the contrary, both onset, offset and midpoint values of PLGA glass transition were reduced in the drug-loaded microparticles, thus confirming the plasticizing effect of prilocaine towards PLGA previously reported by other authors , Delplace et al., 2012 , Gasmi et al., 2015 . On the other hand, the absence of the drug melting peak in the thermal curve of such sample can be reasonably attributed to the almost complete dissolution of the drug within the PLGA polymeric matrix, as reported by other authors (Delplace et al., 2012 , Gasmi et al., 2015 , and as previously observed by SEM analysis. To further corroborate this, it has been verified that the melting peak of the pure drug appeared basically unchanged also applying the heat-cool-heat loop procedure. This proved that the disappearance of prilocaine melting peak in the thermal curve of drug-loaded microparticles is not due to its amorphization after the heating and quenching procedure during the DSC analysis.
In vivo studies
The block of Cutaneous Trunci Muscle Reflex (CTMR) by subcutaneous injection of the given concentration of anesthetic in 0.6 mL solution was used as a model of infiltration anesthesia in rats. The injections were done under the dorsal surface of the thoracolumbar region and the local anesthetic effect was quantitatively evaluated by 6 pinprick tests. The complete absence of 6 responses was defined as 100% CTMR block (i.e. 100% of maximum possible effect, MPE). The pinprick tests were applied every 15 min until full CTMR recovery.
In order to evaluate the dose-effect response of the drug, different prilocaine.HCl concentrations were initially tested (Fig. 4) . A 0.05% drug concentration produced a small block of CTMR (∼30% MPE) 15 min after administration, which disappeared after only 45 min. On the contrary, a 0.1% drug concentration induced a significant CTMR blockage (∼85-90% MPE) between 15 and 60 min after administration, still significant after 90 min (MPE ∼ 40%). The best results, as expected, were obtained with the highest drug concentrations of 0.3% and 0.5%, which produced similar effects, both almost fully blocking the CTMR (∼85-100% MPE) between 15 and 75 min after administration, and allowing maintenance of a significantly high block (∼40-60% MPE) up to 105 min, while the effect vanished at 2 h. The injection of vehicle alone (pH 7.4 phosphate buffer solution, PBS) did not produce any effect. Fig. 5 shows a comparison between the effects of prilocaine.HCl at 0.1% and 0.3% and those induced by the same drug concentrations formulated as prilocaine base loaded in PLGA microparticles. As it appears evident, the administration of the base form of the drug as PLGA microparticle formulation gave rise to a clear improvement of its therapeutic efficacy, in terms of both intensity and duration of the anesthetic effect with respect to the same dose of the hydrochloride salt aqueous solution. In fact, even though the maximum intensity of the effect was reached slightly later (45 min vs 30 min for prilocaine.HCl), the effect of prilocaine as microparticle formulation was significantly more intense and more lasting, particularly for the 0.3% concentration (240 vs 120 min for prilocaine.HCl).
These findings were further corroborated by comparing the values of the areas under the % MPE versus times curves (AUC). In fact, the AUC of prilocaine as microparticle formulation at the concentration of 0.1% was about 32% higher than that of prilocaine.HCl at the same concentration and not significantly different (P > .05) from that of prilocaine.HCl at 0.3%. Moreover, the AUC of prilocaine as microparticle formulation at the concentration of 0.3% was about 60% higher than that of prilocaine.HCl at the same concentration Finally, in order to exclude any possible influence of the polymer used for the microparticle formulation on local anesthesia, the effect of the administration of the polymer without drug (drug-free microparticles) was evaluated. Administration of drug-free PLGA microparticles did not elicit any effect in rats.
Conclusions
A parenteral formulation of prilocaine as free base was successfully developed by encapsulation of the anesthetic drug into polymeric biocompatible and biodegradable microparticles prepared with PLGA by a double emulsion preparation method. Drug-loaded microparticles exhibited homogeneous dimensions, with mean diameters around 26 µm, thus being well suitable for subcutaneous injection using a 23G needle. In vitro drug release tests, carried out under physiological conditions of temperature and pH, showed that the drug release pattern was characterized by an initial rapid release of the drug (about 80% of prilocaine released within the first 24 h), followed by a slow release phase, reaching 100% release after about 72 h. DSC studies allowed to exclude any possible negative effect on the microparticles formulation stability due to the preparation protocol, and evidenced a lowering of the PLGA glass transition temperature, due to a plasticizing effect of prilocaine towards the polymer, as well as the disappearance of the drug melting peak, attributed to its almost complete dissolution into the polymer matrix (Delplace et al., 2012; Gasmi et al., 2015) .
In vivo studies performed in rats proved the actual significant improvement in therapeutic efficacy obtained by encapsulation of prilocaine free base in PLGA microparticles, in terms of both intensity and duration of the anesthetic effect. In particular administration of prilocaine base at 0.3% as microparticle formulation enabled an increase of 1.6 times of AUC and 2 times of duration of the anesthetic effect compared to the administration of the same dose of the hydrochloride salt aqueous solution.
In conclusion, entrapment in PLGA microparticles allowed the development of a parenteral formulation of prilocaine free base in an aqueous vehicle, and proved to be an excellent and simple strategy not only for overcoming problems of poor drug stability, but also for enhancing its therapeutic efficacy. Therefore, the developed formulation represents a good choice to replace the use of vasoconstrictors for the prolongation of the drug-anesthetic effect.
